TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients
TU7710 has the potential to be a highly effective and long-acting treatment for bleeding episodes as well as for preventing ...